Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Chicago reports first rabies-positive dog in 61 years. What we know. - 2Tech giants accused of not complying with Australian social media ban
- 3Rediscovering Imagination in Adulthood: Individual Creative Excursions
- 45 Arising Professions in Environmentally friendly power
- 5How do my eyes adjust to the dark and how long does it take?
- Careful Living: Embracing the Current Second
- ‘Wicked: For Good’ streaming release — How to watch the sequel starring Ariana Grande and Cynthia Erivo
- Dick Van Dyke shares his secrets to longevity as he turns 100
- Windows to the Previous: An Excursion Through the World's Notable Engineering
- Solid Living Tips: Experiences from a Wellness Fan
- Building a Flourishing Business: Illustrations from Business people
- Scientists document a death from a meat allergy tied to certain ticks
- 'Everyone in this prison has had family killed or shot'
- Gulf countries roll out more autonomous taxis
